Thu, April 7, 2022

Uy Ear Maintained (ARQT) at Strong Buy with Decreased Target to $57 on, Apr 7th, 2022

Uy Ear of Mizuho, Maintained "Arcutis Biotherapeutics, Inc." (ARQT) at Strong Buy with Decreased Target from $58 to $57 on, Apr 7th, 2022.

Uy has made no other calls on ARQT in the last 4 months.



There is 1 other peer that has a rating on ARQT. Out of the 1 peers that are also analyzing ARQT, 0 agree with Uy's Rating of Hold.



This is the rating of the analyst that currently disagrees with Uy


  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $37 on, Wednesday, March 2nd, 2022